immuno-oncology Archives -

Close-up image of a firm handshake between two colleagues

Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China’s Sichuan

Merck snaps up cancer drug from China’s Kelun in $1.4bn deal

https://pharmaphorum.com/news/merck-snaps-up-cancer-drug-from-chinas-kelun-in-1-4bn-deal/

BMS doubles down on BridgeBio alliance on SHP2 drugs

Phil Taylor BridgeBio Pharma, Bristol-Myers Squibb, immuno-oncology, Oncology, Opdivo, partnering, SHP2 0 Comment

Bristol-Myers Squibb’s flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting

BMS doubles down on BridgeBio alliance on SHP2 drugs

https://pharmaphorum.com/news/bms-doubles-down-on-bridgebio-alliance-on-shp2-drugs/

News/ News/ News/ Oncology/ R&D

Roche’s TIGIT ambitions take another blow

Phil Taylor immuno-oncology, Non-small cell lung cancer, Oncology, Roche, TIGIT, tiragolumab 0 Comment

Roche’s anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its

Roche’s TIGIT ambitions take another blow

https://pharmaphorum.com/news/roches-tigit-ambitions-take-another-blow/

News/ News/ News/ Oncology/ R&D

Nykode vaccine shows its worth in cervical cancer trial

Phil Taylor cancer vaccine, cervical cancer, HPV, immuno-oncology, Nykode Therapeutics, Oncology, Vaccibody 0 Comment

Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds

Nykode vaccine shows its worth in cervical cancer trial

https://pharmaphorum.com/news/nykode-vaccine-shows-its-worth-in-cervical-cancer-trial/

Market Access/ News/ News/ News/ Oncology

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

Phil Taylor AstraZeneca, biliary tract cancer, Imfinzi, immuno-oncology, Oncology 0 Comment

The FDA has kicked off a priority review of AstraZeneca’s checkpoint inhibitor Imfinzi for biliary tract cancer (BTC),

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

https://pharmaphorum.com/news/az-eyes-q3-fda-decision-for-imfinzi-in-biliary-tract-cancer/

Market Access/ News/ News/ News/ Oncology

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Phil Taylor CAR-T therapies, cell therapy, Gilead Sciences, immuno-oncology, Kymriah, Novartis, Oncology, regulatory approval, Yescarta 0 Comment

Novartis’ CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of

Kymriah is first CAR-T cleared for follicular lymphoma in EU

https://pharmaphorum.com/news/kymriah-is-first-car-t-cleared-for-follicular-lymphoma-in-eu/

Events/ Events/ Oncology

4th Annual Cell Engager Summit | May 24-26 | Boston, MA

Rosie Andre cell engager, immune-oncology therapeutics, immuno-oncology, IO therapeutics, T-cell 0 Comment

Learn from the pioneers of immunotherapy

4th Annual Cell Engager Summit | May 24-26 | Boston, MA

https://pharmaphorum.com/events/4th-annual-cell-engager-summit-may-24-26-boston-ma/

News/ News/ News/ Oncology/ R&D

Gilead dives deeper into NK cell therapies with Dragonfly deal

Phil Taylor Dragonfly, Gilead Sciences, immuno-oncology, natural killer cell, Oncology, partnering 0 Comment

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to

Gilead dives deeper into NK cell therapies with Dragonfly deal

https://pharmaphorum.com/news/gilead-dives-deeper-into-nk-cells-with-dragonfly-deal/

Market Access/ News/ News/ News/ Oncology

FDA says no to two more China-developed cancer drugs

Phil Taylor China, Coherus, fda, HutchMed, immuno-oncology, Oncology, regulatory 0 Comment

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what

FDA says no to two more China-developed cancer drugs

https://pharmaphorum.com/news/fda-says-no-to-two-more-china-developed-cancer-drugs/

Trending

immuno-oncology

Login